



MERUS ANNOUNCES RE-ELECTION OF DIRECTORS

Toronto, Ontario – March 21, 2017 -- Merus Labs International Inc. (“**Merus**” or the “**Company**”) [TSX: MSL, NASDAQ: MSLI] reported today the results of its 2017 annual general and special meeting of shareholders held on March 21, 2017.

All directors nominated, as listed in the Company’s management information circular dated February 15, 2017 (the “**Information Circular**”), were re-elected as members of the board as follows:

DIRECTOR	VOTES FOR*	% FOR	WITHHELD VOTES*	%
Michael Cloutier	55,014,419	99.70%	165,368	0.30%
Robert S. Pollock	55,006,380	99.69%	173,407	0.31%
Timothy G. Sorensen	54,994,235	99.66%	185,552	0.34%
David D. Guebert	55,018,949	99.71%	160,838	0.29%
Theresa Firestone	55,018,300	99.71%	161,487	0.29%
Barry Fishman	55,014,516	99.70%	165,271	0.30%
Robert Bloch	55,001,680	99.68%	178,107	0.32%

** Reflects votes represented by proxy*

In addition, shareholders of the Company approved:

- the appointment of MNP LLP, Chartered Accountants, as the auditor of Merus to hold office until the next annual meeting of shareholders,
- the amendments to the Company’s stock option plan announced on March 13, 2017,
- the continuation of the Company’s stock option plan for an additional three year term, and
- the amendments to the Company’s articles, as described in the Information Circular, by special resolution

About Merus Labs

Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.

For Further Information

Phone: (905) 726-0995

Email: info@meruslabs.com

Website: www.meruslabs.com